knowledge -WSS

knowledge

author：leisure time 2025-10-02 20:53:13 - browse：1

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Doudna institute plans to 'cure hundreds of diseases' with CRISPR

explore

WSS

A new initiative will help leaders fight the next pandemic

Three issues to watch in global health in 2024

Take antibiotics after sex, CDC recommends for certain risk groups

Stopping antidepressants leads to symptoms for 1 in 6 patients

Heart disease and mental health: A look at cardiac psychology

A new initiative will help leaders fight the next pandemic

hotspot

knowledge

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Medicare details structure of new drug price negotiation program

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Apple is now the first public company to be valued at $3 trillion

Sutter Health’s antitrust win overturned by appeals court

Affirmative action in medical school literally saved lives

Stopping antidepressants leads to symptoms for 1 in 6 patients

What does generative AI mean for health care? We asked experts

For pregnant people, addiction treatment shouldn't mean a call to child protective services

focus

Health and fitness trackers are measuring the wrong things

Health and fitness trackers are measuring the wrong things

STAT wants to know your pick for a great summer read or listen

Take antibiotics after sex, CDC recommends for certain risk groups

FTC loses bid to block Novant's North Carolina hospital merger

Structure Therapeutics oral GLP

explore

leisure time

explore

knowledge